Basic Information
Zometa
Regulatory Information
EMEA/H/C/000336
March 20, 2001
December 14, 2000
39
October 29, 2024
Company Information
Ireland
Suite 12, Bunkilla Plaza, Bracetown Business Park, Clonee, County Meath,
Phoenix Labs
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication - Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; - treatment of tumour-induced hypercalcaemia (TIH); - prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; - treatment of tumour-induced hypercalcaemia (TIH); - prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone; - treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).